SCHEDULE: Wasatch Advisors LP Reports 6.8% Stake in C4 Therapeutics

Wasatch Advisors LP has reported a 6.8% beneficial ownership stake in C4 Therapeutics Inc., holding 4,852,741 common shares.

Summary

• Wasatch Advisors LP beneficially owns 4,852,741 shares of C4 Therapeutics Inc. common stock.
• This ownership represents 6.8% of the class of securities.
• Wasatch Advisors LP holds sole voting power over 4,312,039 shares and sole dispositive power over 4,852,741 shares.
• The filing is an Amendment No. 5 to Schedule 13G, indicating an update to a previously reported ownership position.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor and does not contain information that would significantly alter the fundamental outlook or sentiment towards the company.

Positives

• Wasatch Advisors LP, an investment adviser, maintains a significant 6.8% stake in C4 Therapeutics Inc., which may signal institutional confidence in the company's long-term prospects.

Future Outlook

NA

Industry Context

This filing indicates an institutional investor's position in C4 Therapeutics Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such disclosures are routine for significant shareholders and provide transparency on ownership structures within the industry.

Stakeholder Impact

• Shareholders may view Wasatch Advisors LP's continued significant stake as a positive signal of institutional confidence in C4 Therapeutics Inc.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership by Wasatch Advisors LP in C4 Therapeutics Inc. It indicates an institutional investor's continued significant stake, which can be viewed as a neutral to slightly positive signal, but does not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate for existing investors.

Keywords

C4 Therapeutics, Wasatch Advisors, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Investment Adviser